Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) are only two of the Gram-positive bacteria that have attracted a lot of attention to the class of synthetic antibiotics known as oxazolidinone antibiotics. Their distinct mode of action and advantageous safety profile provide them invaluable supplements to the collection of antibiotics employed in the fight against severe illnesses. The first oxazolidinone to be approved for clinical usage, Linezolid, is one of the class's pioneering medications. By attaching itself to the 50S subunit's 23S ribosomal RNA and blocking the development of the initiation complex for protein synthesis, linezolid inhibits the production of proteins by bacteria. Its effectiveness against bacteria resistant to many drugs is attributed to its unique mechanism, which sets it apart from other antibiotic classes. Linezolid is frequently used to treat nosocomial pneumonia, severe infections caused by Gram-positive bacteria, and complex skin and soft tissue diseases. Treatment options for both inpatients and outpatients are provided by its oral and intravenous forms. The possibility of myelosuppression, particularly with prolonged therapy, restricts its use. Throughout treatment, routine monitoring of total blood counts is advised. Tedizolid is a second-generation oxazolidinone that is noteworthy for its ability to overcome the drawbacks of Linezolid. Tedizolid demonstrates heightened efficacy against several Gram-positive bacteria, encompassing strains that are resistant to Linezolid. It functions by preventing the production of new proteins, just like Linezolid. However, because of its longer half-life, it can be used once daily, which may increase patient compliance and convenience. Tedizolid is a viable therapy option for acute bacterial skin and skin structure infections (ABSSSI) and hospital-acquired pneumonia (HAP), including MRSA-caused infections, due to its increased spectrum of activity and advantageous pharmacokinetic features. Additionally, it has shown effective in treating infections brought on by Enterococcus faecalis and faecium strains that are resistant to vancomycin. But even with their effectiveness, oxazolidinones have disadvantages. Extended usage may cause resistance, which calls for cautious application and close observation. They also have negative side effects such peripheral neuropathy, headaches, and gastrointestinal problems. When administering these antibiotics, it is important to carefully weigh the risk-benefit profile, especially for patients who are receiving concurrent drugs or have pre-existing illnesses. To sum up, oxazolidinone antibiotics are an effective treatment choice for illnesses brought on by Gram-positive bacteria that are resistant to treatment. Their distinct mode of action, extensive range of effects, and generally advantageous safety profile render them valuable instruments in the battle against antibiotic resistance. Nonetheless, the possibility of side effects and the emergence of resistance underscores the significance of cautious application and continuous investigation into innovative antimicrobial drugs.